Signature Pharmaceuticals Limited was established in 1995 in Mumbai India. It has since gone on to cement its place both nationally and internationally in the pharmaceutical industry. Its values are based on an unwavering commitment to quality, accessibility and affordability. From research and manufacturing to sales and marketing, the goal is to build trust with healthcare professionals, regulators, and patients.
Signature Pharmaceuticals upholds these values through rigorous, tangible actions. They meet their quality commitment by adhering to strict Current Good Manufacturing Practices (CGMP), operating state-of-the-art facilities, and implementing robust quality control systems at every stage of production. Accessibility is achieved by investing in efficient, large-scale manufacturing processes for off-patent drugs, which significantly reduces costs compared to original branded medications.
Signature operates across diverse international markets, supplying essential medicines to hospitals, pharmacies, and distributors in numerous countries. This involves navigating a complex web of regulatory requirements, from the FDA in the United States and the EMA in Europe to national health authorities in Asia, Africa, and Latin America. Through a network of manufacturing sites and strategic partnerships, Signature is on hand to respond to any global health needs.
The core of Signature Pharmaceuticals' business is the production of generic medicines, which play a vital role in modern healthcare. Generics are bioequivalent to brand-name drugs, meaning they deliver the same clinical benefits, but are sold at a fraction of the cost after the original patent expires. This price reduction is crucial. It eases the financial burden on patients. By making life-saving and life-maintaining treatments affordable, Signature Pharmaceuticals is proud to play a key role in ensuring access to essential medicine worldwide.
